Achieve Life Sciences Inc Cash Flow-to-Debt Ratio
Achieve Life Sciences Inc cash flow-to-debt ratio. Achieve Life Sciences Inc (SP4P) has a Cash Flow-to-Debt Ratio of -0.31x as of March 2026, meaning its operating cash flow of €-6.93 Million could theoretically repay 0% of its total liabilities (€22.43 Million) in one year. See how financially flexible is Achieve Life Sciences Inc to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Achieve Life Sciences Inc (2016–2025)
Cash flow-to-debt ratio of Achieve Life Sciences Inc from 2016 to 2025. Historical debt coverage capacity for Achieve Life Sciences Inc across 10 annual periods. Also explore Achieve Life Sciences Inc annual equity growth to track the company's year-over-year net asset growth rate.
Achieve Life Sciences Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Achieve Life Sciences Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Achieve Life Sciences Inc. For the full cash flow conversion analysis, see cash flow conversion of Achieve Life Sciences Inc.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.44x | €-49.47 Million | €20.27 Million | ▼ -45.4% |
| 2024 | -1.68x | €-29.77 Million | €17.73 Million | ▼ -42.8% |
| 2023 | -1.18x | €-24.48 Million | €20.82 Million | ▲ +32.1% |
| 2022 | -1.73x | €-37.55 Million | €21.67 Million | ▼ -14.6% |
| 2021 | -1.51x | €-29.44 Million | €19.47 Million | ▲ +66.2% |
| 2020 | -4.47x | €-13.47 Million | €3.01 Million | ▲ +11.0% |
| 2019 | -5.03x | €-15.22 Million | €3.03 Million | ▼ -55.3% |
| 2018 | -3.24x | €-10.62 Million | €3.28 Million | ▲ +28.5% |
| 2017 | -4.52x | €-9.11 Million | €2.01 Million | ▼ -18946.0% |
| 2016 | -0.02x | €-202.00K | €8.50 Million | — |